


REVISION OF ANTIMICROBIALS

AWaRE CLASSIFICATION

Diagram of Antibiotic Target and Resistance Mechanisms



Mechanisms of Antibiotic Resistance in Bacteria

Mechanisms of ATB Resistance

NATURAL/INTRINSIC

- Intrinsic resistance is **when a bacterial species is naturally resistant to a certain antibiotic or family of antibiotics, without the need for mutation or gain of further genes**. This means that these antibiotics can never be used to treat infections caused by that species of bacteria. Intrinsic resistance usually **mediated by the bacterial outer membrane** but also by antibiotic efflux.

MAIN ACQUIRED RESISTANCE MECHANISMS



- 1. ENZYMATIC INACTIVATION OF ANTIBIOTICS
- 2. ANTIBIOTIC MODIFICATION
- 3. ALTERED TARGET SITE
- 4. MECHANISMS OF ANTIBIOTIC EFFLUX
- 5. DECREASED PERMEABILITY OF BACTERIAL MEMBRANES

ACQUIRED MECHANISMS OF RESISTANCE


- Microbial genetic variability through variety of mechanisms (**point mutations, rearrangement of large DNA segments – inversions, duplications, insertions, deletion or transpositions** usually generated by integrons, transposons, insertion sequences, acquisitions of foreign DNA carried by plasmids, bacteriophages, naked DNA sequences, transposable genetic elements) is **essential for microbial evolution to occur**
- **Antimicrobials (ATB) exert strong selective pressures on microbial populations**
- **ATB resistance genes were present in the era before ATB therapy was available – probably originated from antibiotic-producing bacteria**
- **These resistant bacterial populations spread ATB resistance vertically to subsequent generations and horizontally to susceptible strains of related bacteria, even to different species or genera**

Plasmids

- **Extrachromosomal elements** – agents of genetic exchange and resistance-gene dissemination
- **Autonomously replicating** – double-stranded DNA circular, covalently closed (10-400 kbp)
- Extremely **common in bacteria**, **multiple copies** of specific plasmid **or multiple different plasmid** – in a bacterial cell
- ***tra* genes needed for transfer** make conjugative plasmids larger
- **small plasmids** using conjugation **apparatus from coresident conjugative plasmids or conjugative transposons**



Plasmids




Ref: <https://www.frontiersin.org/articles/10.3389/fmicb.2020.00761/full>

Transposable genetic elements (transposons - Tn, insertion sequences – IS)

- Transposons translocates a unit **from one area of the bacterial chromosome to another or between the chromosome and plasmid or bacteriophage DNA**
 - **Transposable genetic elements** possess **specialized system of recombination** (recA independent recombination system) **transposase – occurs between nonhomologous sequences of DNA, results in wholesale modifications of large sequences of DNA**
 - **Tn, IS (except conjugative transposons) – incapable of autonomous self-replication and must exist on a replicon** (chromosome, bacteriophage, plasmid)
-
- **Transposition is a continuous, ongoing process** in bacterial population (e.g. spread of tetracycline-resistance Tn among *N. gonorrhoeae*, *Mycoplasma hominis* and *Ureoplasma urealyticum*; *vanA* gene mediated in enterococci by a composite transposon)
 - **Transposons – essential in the evolution of resistance plasmids**


Structure of transposable genetic elements (transposons - Tn, insertion sequences – IS)

Insertion Sequence (IS)



The insertion sequence (IS) is the smallest transposon present in bacterial chromosomes and plasmids. It is composed of two inverted repeats (IR) flanking genes necessary for transposition.

Composite Transposon




The composite transposon is composed of two IS elements flanking a central protein coding DNA region. This central region often contains genes for antibiotics resistance

DNA Integration Elements


- **Integrans** - ATB resistance genes are often closely linked, may exist in tandem along bacterial chromosome or plasmid
- **Principal role** – provide a convenient **insertion site for ATB resistance genes from foreign DNA sources**
- **Integrans** - often exist **near promoter site**
- **recombinational „hot spots“ for site-specific recombination events between large nonhomologous sequences**
- **Own integrase function (integrated specialized attachment and integration site – from 57 – 141 bp) – mediated ATB resistance genes from mobile gene cassettes**
- **Frequency of transcription of integrated cassettes of ATB resistance genes depends on proximity to the promoter at the 5' upstream end of the region**

General structure of class 1 integrons




General structure of class 1 integrons. Cassettes are inserted in the variable region of integrons by a site-specific recombination mechanism. The *att11* and *attC* sites are shown by a vertical rectangle and oval, respectively, and promoters are denoted by P_{int}, P_c and P. Integrated cassettes are composed of a gene and an *attC* recombination site. Genes are as follows: *int11*, integrase gene; *qacEΔ1*, antiseptic resistance gene; *su11*, sulphonamide resistance gene; *orf5*, gene of unknown function.

Diagram of Antibiotic Target and Resistance Mechanisms




Ref: Cardoso P. Molecular engineering of antimicrobial peptides: microbial targets, peptide motifs and translation opportunities, 2021

Diagram of Antibiotic Target and Resistance Mechanisms



1. ENZYMATIC INACTIVATION OF ANTIBIOTICS


- **Betalactamases**
- a) **resistance to betalactams primarily occurs through betalactamases** – splitting the amide bond of the betalacm ring
- b) Extended-Spectrum Betalactamases
- c) Carbapenemases



Ref: https://tmedweb.tulane.edu/pharmwiki/doku.php/betalactam_pharm

- Most likely **co-evolved with bacteria as mechanisms against natural antibiotics**
- Selective pressure exerted by **widespread use of ATB** have **accelerated** their **development** and **spread**
- Can be **located** either on **chromosomes** or transferable genes locate on **plasmids** or **transposons**, **integrons** (can facilitate MDR resistance).
- **Classification** (Ambler – according to their **amino acid structure** A-D or Bush-Jacoby-Medeiros according to **functional substrate profile and susceptibility to inhibitors**)

Betalactamases structure



Ref: Ghafourian S., Extended Spectrum Beta-lactamases, Curr. Issues Mol. Biol. (2015) 17: 11-22.

Ambler classification of betalactamases (classes A – D)

	Active site	Enzyme Type	Substrates	Examples
A	Serine	Penicillinases Broad-spectrum	benzylpenicillin, aminopenicillins, carboxypenicillins, ureidopenicillins, narrow-spectrum cephalosporins	PC1 in <i>S. aureus</i> , TEM-1, SHV-1 in <i>E. coli</i> , <i>K. pneumonia</i> and other Gramneg. bacteria
		Extended-spectrum (ESBL)	Substrates of broad-spectrum plus oxyimino-betalactams (cefotaxime, ceftazidime, ceftriaxone), aztreonam	e.g. <i>E. coli</i> (derived from TEM, SHV, CTX-M), <i>P. aeruginosa</i> IBC-2
		Carbapenemases	Substrates of ESBL plus cephamycins (e.g. cefuroxime) and carbapenems	e.g. <i>K. pneumoniae</i> KPC-1, 2, 3
B	Metallo- β -lactamases (Zn ²⁺)	Carbapenemases	Substrates of ESBL plus cephamycins (e.g. cefuroxime) and carbapenems	e.g. VIM, IMP, SIM lineages in <i>P. aeruginosa</i>
C	Serine	Cephalosporinases	Substrates of ESBL plus cephamycins (e.g. cefuroxime)	e.g. AmpC-type enzymes in Enterobacteriaceae, <i>Acinetobacter</i>
D	Serine	Oxacillinases		
		Broad-spectrum	aminopenicillins, ureidopenicillins, oxacillin, some narrow-spectrum cephalosporins	e.g. OXA family in <i>P. aeruginosa</i>
		Extended-spectrum	Spectrum of broad-spectrum plus oxyiminobetalactams (cefotaxime, ceftazidime) and monobactam (aztreonam)	e.g. OXA-derived in <i>P. aeruginosa</i>
				e.g. OXA-derived in <i>Acinetobacter</i>

Note: Classification A – C is most relevant for medical students to know

Betalactamases

- One of the first betalactamase described was **penicillinase in *S. aureus*** (could be used and inhibitor b-lactamase–b-lactamase inhibitor complex binding the enzyme). **High levels of resistance to penicillin (80-95%)** are standard **for community strains** in almost all countries now.
- **In Gramnegative bacteria** – rise in **ampicilin** in 1960s emergence of TEM-1 (Greek patient Temoneira), plasmid encoded, was later disseminated as **family TEM betalactamases in *P. aeruginosa*, Enterobacteriaceae, *H. influenzae*, *N. gonorrhoeae*.**
- **Similarly chromosomally- and plasmid-mediated SHV-type betalactamases** (molecular structure similar to TEM) became **widely prevalent among *E. coli* and *K. pneumoniae*.**
- **Third-generation cephalosporins were stable to them but ESBL are capable of hydrolyzing broad-spectrum cephalosporins and monobactam (aztreonam).**
- In addition, **increasing reports of carbapenemases** have arisen **concern about currently limited number of antimicrobial arsenal against infection caused by MDR Gramnegative bacteria.**

ESBL

- **TEM-derived:** the most common in Gramneg. bacteria, hydrolyze penicillin and narrow-spectrum cephalosporins in Enterobacteriaceae, *N. gonorrhoeae*, *H. influenzae*. ESBL is obtained through changes in a single or few amino acids that alter configuration of the enzyme active site more accessible to oxyimino-side chain of 3rd cephalosporines (more than 160 enzymes, primarily in *E. coli*, *K. pneumoniae*, majority TEM-derived ESBL remain susceptible to clavulanic acid)
- **SHV-derived:** SHV-1 similar to that of TEM-1, primarily in *K. pneumoniae*
- **CTX-M-derived:** probably acquired by plasmid from the chromosomal AmpC enzymes of low pathogenic Gram-negative rod *Kluyvera*, hydrolyze cefotaxime, ceftriaxone, ceftazidime, most prevalent in Europe and South America
- **OXA-derived ESBL:** hydrolyze oxacillin and its derivative, described mainly in *P. aeruginosa*
- **AmpC enzymes:** primarily chromosomal enzymes that confer resistance to penicillins, narrow-spectrum cephalosporins, oxyimino-betalactams, cephamycins (e.g. cefoxitin), not susceptible to inhibitor of betalactamases (detected in some clinical strains of e.g. *Enterobacter*, *Citrobacter*, *Serratia*)

SIGNIFICANT NOTE: if we do not know what type of broad-spectrum beta-lactamase the bacterium produces, we cannot use beta-lactam with a beta-lactamase inhibitor in treatment !!!

Carbapenemases

- confer resistance the largest ATB spectrum
- **KPC the most important carbapenemases** (initially reported *K. pneumoniae*)
- **Resistant to inhibitors** - clavulanic acid, tazobactam, sulbactam
- Confer resistance to all **betalactams and monobactam**
- **chromosomally encoded metallo-betalactamases (e.g. VIM, IMP...) primarily found in environmental isolates of *Aeromonas*, *Chryseobacterium* and *Stenotrophomonas***
- **typically transmitted by mobile genetic elements (MGE)** inserted into **integrans** – have spread through *P. aeruginosa*, *Acinetobacter*, other Nonfermenters and enteric bacterial pathogens
- class D carbapenemases (OXA – 23,24,40,58) primarily found in *Acinetobacter*

2. ANTIBIOTIC MODIFICATION

- **Aminoglycoside (AMG) Resistance-Modifying Enzymes** (more than 30 enzymes)
- AMG resistance is **the most commonly caused by modifying enzymes**
- encoded **on plasmid or chromosome**
- **3 general reactions: N-acetylation, O-nucleotidylation, O-phosphorylation** (attack specific amino or hydroxyl group)
- **Nomenclature: where the modification occurs**
- Modification of ATB during transport across the cytoplasmic membrane
- **APH (3') and APH (3'')** distributed widely among **Grampositive** and **Gramnegative** bacteria
- **AAC(6')APH(2')** is a **bifunctional enzyme (acetylation/phosphorylation)** widespread in **staphylococci** and **enterococci**), residing in a common transposon Tn4001

Representative aminoglycosides and modification sites by AAC, ANT, and APH enzymes




Fig. An example of each kind of modification is shown on one of the substrates. The square and oval on positions 2' and 6'' in paromomycin I indicate that although this molecule is preferentially acetylated at the position 1, 1,2'-di-N-acetylparomomycin and 1,6''-di-N-acetylparomomycin are also found as products of the enzymatic reaction (Sunada et al., 1999). AAC(3)-X can catalyze acetylation at the 3''-amino group in arbekacin and amikacin (Hotta et al., 1998). (Ref: <https://www.sciencedirect.com/science/article/pii/S1368764610000385#fig0005>)

Mechanisms of Chloramphenicol Resistance

- **Chloramphenicol acetyltransferase (plasmid- or chromosome-borne) and acetylation** is primary mechanism of the resistance in **Grampositive** and **Gramnegative bacteria**

Macrolide-, Linkosamide-, Streptogramin- Inactivating Enzymes

- **Erythromycin esterases – hydrolyse the lactone ring** and limit **erythromycin** and **other macrolides** use to treat **Gramnegative** bacterial pathogens


Mechanisms of Tetracycline Inactivation

- **TetX enzyme found in Bacteroides inactivating tetracycline** (it is unusual mechanisms)

3. ALTERED TARGET SITE

- **e.g. Macrolides, Lincosamides, Streptogramins** – disrupts its ability to inhibit protein synthesis and bacterial cell growth, principal mechanism of multiple-agent resistance to MLSb antibiotics among aerobic and anaerobic Grampositive bacteria (e.g. *S. aureus*, *S. pneumoniae*, *C. perfringens*...), may **be located on plasmids or chromosomes**
- ***erm* (A, B, C) genes** determined the **methylases that dimethylate adenine residues on the 23S ribosomal RNA (50S subunit) disrupting binding of MLS antibiotic to the ribosome**
- **Oxazolidones (linezolid):** determined by **point mutation within the gene encoding 23S rRNA** of the 50S ribosomal subunit (described in *S. aureus*, *S. epidermidis*, enterococci)
- **Vancomycin resistance: alteration of cell wall precursor in enterococci** determined by ***vanA* gene** (rarely also in staphylococci as VRSA), thickened cell walls in VISA (vankomycin resistant *S. aureus*)
- **Alteration of target enzymes: *mecA*** located on **staphylococcal cassette chromosome *mec* (SCCmec)** (located chromosomally) determines alternative PBP2a
- **PBPs changes** also known in betalactams resistant *N. gonorrhoeae*, *N. meningitidis*, *S. pneumoniae*
- **Quinolones** – **mutations in *gyrA* and/or topoisomerase IV** lead to the resistance in Enterobacteriaceae or *P. aeruginosa*

Mechanism of Macrolides, Lincosamides, Streptogramins Resistance




Ref: https://www.researchgate.net/figure/Mechanisms-of-bacterial-resistance-to-macrolide-lincosamide-streptogramin-antibiotics_fig1_257769651

Resistance to colistin in Gramnegative rods

The mechanism of resistance of the MCR gene is a **phosphatidylethanolamine transferase**. The enzyme **transfers a phosphoethanolamine residue to the lipid A** present in the **cell membrane of gram-negative bacteria**. The altered lipid A has much lower affinity for colistin and related polymyxins resulting in reduced activity of the antimicrobial. Although the same mechanism has been observed before with enzymes like eptA, mcr-1 is the first polymyxin resistance gene known to be capable of **horizontal transfer between different strains of a bacterial species**.


Mechanisms of resistance to colistin



4. MECHANISMS OF ANTIBIOTIC EFFLUX

- **Specific or multidrug resistance mechanisms decreasing effective concentration of ATB in the bacterial cell**
- **Tetracyclines:** the most commonly in enteric pathogens (e.g. *E. coli*, *Shigella*...)
- Energy dependent proces (membrane transporter system)
- The genes (*tet*) located on the **chromosome, plasmids or transposable elements**
- **Macrolides, Streptogramins, Azalides (azithromycin):** Efflux mechanism mediated by *mef* (in **Streptococci**) and *msrA* (in **Staphylococci**) are responsible for the resistance
- **Betalactams:** multidrug efflux pump in inner and outer membrane is known in **P. aeruginosa**
- **Fluoroquinolones:** detected in enteric bacteria and staphylococci, determining by a specific quinolone efflux pump (e.g. EmrAB, AcrAB)

Representation of different types of efflux pumps in Gram-positive and Gram-negative bacteria




Ref: <https://healthjade.net/antibiotic-resistance/>

5. DECREASED PERMEABILITY OF BACTERIAL MEMBRANES

- Outer or inner membrane permeability: bacteria can regulate **size** and **number of the porins**
- Relatively **quickly emerged** (during a particular patient treatment, e.g. imipenem/*P.aeruginosa*)
- **The most known in *P. aeruginosa*** determining resistance to aminoglycosides, carbapenems


Modification, reduction and loss of porins



Multidrug-resistance mechanisms among bacteria

- Bacterial pathogen can express **more than 1 resistance mechanism** leading to **multidrug-resistance** or even **pan-resistance**
- In general, **resistance in Gramnegative bacteria** starts with limited outer **membrane permeability coupled with the overexpression of MDR efflux pumps**
- It may allow to survive bacterial pathogen facilitating the **accumulation of new antibiotic-resistance mutations**
- **Clinically important efflux pumps: RND, MFS, SMR** (staphylococcal multiresistance), **MATE family** – **such pumps are widespread** among procaryotes responsible for the export of toxic substances and allowing survival in noxious environment
- **Usually sequentially transferred by multiple-resistant determinants located on mobile genetic elements** (e.g. conjugative transposon Tn916 conferring resistance to tetracycline and chloramphenicol among bacterial species)
- **Integrations usually capture multiple antibiotic resistance genes**, which can insert **resistance gene cassettes** into their attI integration site and are **often found on transposons carried on plasmids, with seemingly endless recombinant potential**

Structure of significant ATB Efflux pumps





AWaRe classification of antibiotics for evaluation and monitoring of use, 2023


- The **AWaRe classification** of antibiotics was **developed** in 2017 by the **WHO Expert Committee on Selection and Use of Essential Medicines** as a **tool to support antibiotic stewardship** efforts at **local, national and global levels**.
- Antibiotics are classified into three **groups, Access, Watch and Reserve**, taking into account the **impact** of different antibiotics and antibiotic classes **on antimicrobial resistance**, to **emphasize the importance of their appropriate use**. It is updated every 2 years.

* The AWaRe classification **monitoring the effects of stewardship policies that aim to optimize antibiotic use** is intended as a tool for **monitoring antibiotic consumption**, defining targets and and curb antimicrobial resistance. The WHO 13th General Programme of Work 2019–2023 includes a country-level target of at least 60% of total antibiotic consumption being Access group antibiotics.



AWaRE : Antibiotics are categorized into three groups

Essential Access, Watch and Reserve antibiotics need to be equally accessible and affordable for those who need them



ACCESS GROUP

[bez názvu]

- first or second choice antibiotics
- offer the best therapeutic value, while minimizing the potential for resistance

WATCH GROUP

- first or second choice antibiotics
- only indicated for specific, limited number of infective syndromes
- more prone to be a target of antibiotic resistance and thus prioritized as targets of stewardship programs and monitoring

RESERVE GROUP

- “last resort”
- highly selected patients (life-threatening infections due to multi-drug resistant bacteria)
- closely monitored and prioritized as targets of stewardship programs to ensure their continued effectiveness




Fig. 1. Roles and tasks of the Working Group and the Expert Committee and their relationship.

References: Moja et al. WHO's essential medicines and AWaRe: recommendations on first- and second-choice antibiotics for empiric treatment of clinical infections, *Clinical Microbiology and Infection*, 2024

ACCESS		WATCH		RESERVE
Aminocyclitols: Spectinomycin	Penicillins: Amoxicillin Ampicillin Azidocillin Bacampicillin Benzathine-benzylpenicillin Benzylpenicillin Clometocillin Cloxacillin Dicloxacillin Epicillin Flucloxacillin Hetacillin Mecillinam Metampicillin Meticillin Nafcillin Oxacillin Penamercillin Phenoxymethylpenicillin Pivampicillin Pivmecillinam Procaine-benzylpenicillin Propicillin Talampicillin	Aminoglycosides: Arbekacin Bekanamycin Dibekacin Isepamicin Kanamycin_IV Kanamycin_oral Micronomicin Neomycin_IV Neomycin_oral Netilmicin Ribostamycin Sisomicin Streptoduocin Streptomycin_IV Streptomycin_oral Tobramycin	Fourth-generation-cephalosporins: Cefepime Cefosolis Cefozopran Cefpirome	Aminoglycosides: Plazomicin
Aminoglycosides: Amikacin Gentamicin			Glycopeptides: Telicoplanin Vancomycin_IV Vancomycin_oral	Carbapenems: Imipenem/cilastatin/relebactam Meropenem/vaborbactam
Amphenicols: Chloramphenicol Thiamphenicol			Lincosamides: Lincomycin	Fifth-generation cephalosporins: Ceftaroline-fosamil Ceftobiprole-medocartil Ceftolozane/tazobactam
Beta-lactam/beta-lactamase-inhibitor: Amoxicillin/clavulanic-acid Ampicillin/sulbactam Sulbactam		Beta-lactam/beta-lactamase-inhibitor_anti-pseudomonal: Piperacillin/tazobactam	Macrolides: Azithromycin Clarithromycin Dirithromycin Erythromycin Fidaxomicin Flurithromycin Josamycin Midecamycin Mocamycin Oleandomycin Rokitamycin Roxithromycin Solithromycin Spiramycin Telithromycin Troleandomycin	Glycopeptides: Dalbavancin Oritavancin Telavancin
Beta-lactamase-inhibitors: Sulbactam		Beta-lactamase-inhibitors: Tazobactam		Glycylcyclines: Tigecycline
First-generation-cephalosporins: Cefacetrile Cefadroxil Cefalexin Cefaloridine Cefalotin Cefapirin Cefatrizine Cefazedone Cefazolin Cefradine Cefroxadine Ceftazole	Sulfonamides: Sulfadiazine Sulfadimethoxine Sulfadimidine Sulfafurazole Sulfalsodimidine Sulfalene Sulfamazone Sulfamerazine Sulfamethizole Sulfamethoxazole Sulfamethoxypyridazine Sulfametomidine Sulfamethoxydiazine Sulfamoxole Sulfanilamide Sulfaperin Sulfaphenazole Sulfapyridine Sulfathiazole Sulfathiourea	Carbapenems: Blapenem Doripenem Ertapenem Imipenem/cilastatin Meropenem Panipenem Tebipenem		Lipopeptides: Daptomycin
Imidazoles: Metronidazole_IV Metronidazole_oral Ornidazole_IV Ornidazole_oral Secnidazole Tinidazole_IV Tinidazole_oral		Fluoroquinolones: Ciprofloxacin Delafloxacin Enoxacin Fleroxacin Garenoxacin Gatifloxacin Gemifloxacin Grepafloxacin Lascufloxacin Levofloxacin Levonadifloxacin Lomefloxacin Moxifloxacin Norfloxacin Ofloxacin Pezufloxacin Pefloxacin Prulifloxacin Rufloxacin Sitafloxacin Sparfloxacin Temafoxacin Tosufloxacin Trovafoxacin	Penicillins: Aspoxicillin Azlocillin Carbenicillin Carindacillin Mezlocillin Pheneticillin Piperacillin Sulbenicillin Temocillin Ticarcillin	Monobactams: Aztreonam Carumonam
Lincosamides: Clindamycin			Phenol derivatives: Clofocetol	Other-cephalosporins: Cefiderocol
Nitrofurans derivatives: Furazidin Nifurtinol			Phosphonics: Fosfomicin_oral	Oxazolidinones: Linezolid Tedizolid
Nitrofurans-derivatives: Nitrofurantoin	Tetracyclines: Doxycycline Tetracycline		Quinolones: Cinoxacin Flumequine Nemonoxacin Oxolinic-acid Pipemidic-acid Piromidic-acid Rosoxacin	Penems: Faropenem
Sulfonamide-trimethoprim combinations: Sulfadiazine/tetroxoprim Sulfadiazine/trimethoprim Sulfadimidine/trimethoprim Sulfamerazine/trimethoprim Sulfamethoxazole/trimethoprim Sulfametrole/trimethoprim Sulfamoxole/trimethoprim	Trimethoprim-derivatives: Brodinoprim Trimethoprim			Phosphonics: Fosfomicin_IV